Literature DB >> 18428663

Assays for cyclic nucleotide-specific phosphodiesterases (PDEs) in the central nervous system (PDE1, PDE2, PDE4, and PDE10).

Chengjun Deng1, Daguang Wang, Bozena Bugaj-Gaweda, Michael De Vivo.   

Abstract

Since the identification of phosphodiesterase activity in brain tissue more than 40 years ago, 11 distinct gene families have been identified, differing with respect to localization, regulation, affinity for cAMP and cGMP, and distinct functions within cells. PDEs 1, 2, 4, and 10 are currently of special interest to CNS pharmacology because of their high expression in specific areas of the brain and the behavioral effects of inhibitors of these enzymes in rodents. Efficient high-throughput PDE enzyme assays are essential for PDE-targeted drug discovery, and this unit details two types of assays. The first method is relatively inexpensive and is based on separating radiolabeled cNMPs from degradation products on alumina columns. The second method is fluorescence-based; it is fast and better accommodates high-throughput screening, but is more expensive. Although these methods have successfully been used for PDEs 1, 2, 4 and 10, they could be readily adapted to other PDEs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18428663     DOI: 10.1002/0471142301.ns0721s38

Source DB:  PubMed          Journal:  Curr Protoc Neurosci        ISSN: 1934-8576


  4 in total

Review 1.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

2.  Inhibition of phosphodiesterase 2 by Bay 60-7550 decreases ethanol intake and preference in mice.

Authors:  Jing Shi; Huaxia Liu; Jianchun Pan; Jie Chen; Nianping Zhang; Kaiping Liu; Ning Fei; James M O'Donnell; Han-Ting Zhang; Ying Xu
Journal:  Psychopharmacology (Berl)       Date:  2018-06-07       Impact factor: 4.530

3.  Cyclic nucleotide signaling in polycystic kidney disease.

Authors:  Xiaofang Wang; Christopher J Ward; Peter C Harris; Vicente E Torres
Journal:  Kidney Int       Date:  2009-11-18       Impact factor: 10.612

Review 4.  Phosphodiesterase type 5 and cancers: progress and challenges.

Authors:  Ines Barone; Cinzia Giordano; Daniela Bonofiglio; Sebastiano Andò; Stefania Catalano
Journal:  Oncotarget       Date:  2017-10-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.